Loading …

ApoRx is a drug discovery company focusing on the discovery, design, characterization, and development of small proteolysis targeting molecules (PTMs) against well-validated disease-causing proteins in cancer and other indications. Our technology is based on a proprietary focus library of RING E3 ligase binders and is designed to harness the intracellular Ubiquitin-Proteasome machinery to degrade and destroy unwanted proteins by Targeted Protein Degradation.
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more